1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE
1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Basic information
- Product Name:
- 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE
- Synonyms:
-
- CFM-2
- 4H-2,3-Benzodiazepin-4-one,1-(4-aminophenyl)-3,5-dihydro-7,8-dimethoxy-
- 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE
- CFM2,CFM 2
- CFM 2, AMPA receptor antagonist
- CFM-2, 10 mM in DMSO
- CAS:
- 178616-26-7
- MF:
- C17H17N3O3
- MW:
- 311.34
- Product Categories:
-
- Glutamate receptor
- Mol File:
- 178616-26-7.mol
1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Chemical Properties
- Density
- 1.32±0.1 g/cm3(Predicted)
- storage temp.
- Store at RT
- solubility
- Soluble in DMSO
- pka
- 12.53±0.40(Predicted)
- form
- Off-white solid.
- color
- Light yellow to khaki
1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE Usage And Synthesis
Uses
CFM-2 is a non-competitive antagonist of the AMPA receptors.
Definition
ChEBI: 1-(4-aminophenyl)-7,8-dimethoxy-3,5-dihydro-2,3-benzodiazepin-4-one is a benzodiazepine.
Biological Activity
Novel, selective non-competitive AMPA antagonist. Highly potent, long-acting anticonvulsant.
in vivo
Pretreatment with CFM-2 delays the progression of seizure rank during repeated administration of pentylentetrazole. At the end of the period of repeated pentylentetrazole treatment (6 weeks) the mean seizure score was 0 in vehicle treated controls, 4.3 in animals treated with vehicle + pentylentetrazole, 2.2 in rats treated chronically with CFM-2 (20 μmol/kg; i.p.) + pentylentetrazole and 1.0 in rats treated repeatedly with CFM-2 (50 μmol/kg; i.p.) + pentylenetetrazole. CFM-2 is also able to antagonize the long-term increase in sensitivity of the convulsant effects of GABA function inhibitors in pentylentetrazole-kindled animals[1].Intrathecal application of two selective non-competitive AMPAR antagonists, CFM-2 (25 and 50 μg) and GYKI 52466 (50μg), significantly attenuated mechanical and thermal hypersensitivities on the ipsilateral hind paw at 2 and 24 h post-CFA injection. Neither CFM-2 nor GYKI 52466 affects the contralateral basal responses to thermal and mechanical stimuli[4].
storage
Room temperature
1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONESupplier
- Tel
- 821-50328103-801 18930552037
- 3bsc@sina.com
- Tel
- 025-83697070
- info@chemlin.com.cn
- Tel
- 1-631-485-4226; 16314854226
- info@bocsci.com
- Tel
- 021-58950125
- info@chemexpress.com
- Tel
- 13120367189
- mychess007@163.com
1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE(178616-26-7)Related Product Information
- (S)-AMPA
- CYCLOTHIAZIDE
- NBQX DISODIUM SALT
- KYNURENIC ACID
- DNQX
- CNQX
- (RS)-AMPA
- 1-[2-(3,4-dimethoxyphenyl)ethyl]hydrazine
- 1-[2-(2-methylphenyl)ethyl]hydrazine
- 3,4-DIMETHOXYPHENYLACETIC ACID HYDRAZIDE
- 2-(3-METHOXYPHENYL)ETHANOHYDRAZIDE
- 1-(3-methoxyphenethyl)hydrazine hydrochloride
- (4-HYDROXY-PHENYL)-ACETIC ACID HYDRAZIDE
- 2-(4-METHOXYPHENYL)ACETOHYDRAZIDE
- (p-Methoxyphenethyl)hydrazine
- 1-(4'-AMINOPHENYL)-3,5-DIHYDRO-7,8-DIMETHOXY-4H-2,3-BENZODIAZEPIN-4-ONE